Anti-proliferative effects of a copper(II) complex with a thiosemicarbazone ligand against selected human cancer cells
dc.creator | Fiadjoe, Hope | en_US |
dc.creator | Lambring, Christoffer B. | en_US |
dc.creator | Sankpal, Umesh | en_US |
dc.creator | Alajroush, Duaa | en_US |
dc.creator | Smith, Chloe | en_US |
dc.creator | Anderson, Brittney | en_US |
dc.creator | Mann, Novia | en_US |
dc.creator | Beebe, Stephen | en_US |
dc.creator | Holder, Alvin | en_US |
dc.creator | Basha, Riyaz | en_US |
dc.date.accessioned | 2023-04-05T13:30:57Z | |
dc.date.available | 2023-04-05T13:30:57Z | |
dc.date.issued | 2023 | en_US |
dc.description.abstract | Purpose: The frequent relapse and drug resistance associated with the current cancer chemotherapy treatments necessitate the development of alternative strategies. Thiosemicarbazones are a class of metal chelators that have been explored to treat diverse human diseases, including cancer. Copper, a crucial structural component for many significant enzymes and a key catalytic co-factor in redox processes, is being explored for several medical applications. Additionally, the anti-cancer activity of certain chemotherapeutic agents can be enhanced by the use of copper-containing complexes. This study aimed to evaluate the antiproliferative effects of a copper(II) complex with a thiosemicarbazone ligand (Cu-acetylethTSC or [Cu(acetylethTSC)Cl]Cl·0.25C2H5OH (where acetylethTSC = (E)-N-ethyl-2-[1-(thiazol-2-yl)ethylidene]hydrazinecarbothioamide)) against human cancer cell lines, viz., medulloblastoma (DAOY, D283), glioblastoma (LN-229), Ewing sarcoma (TC205, CHLA10), and acute lymphoblastic leukemia (CCRF-CEM, SUP-B15). Methods: These selected cell lines were cultured using standard protocols. Cell viability was measured using a Cell Titer-Glo kit at 48 h after treatment with various concentrations of Cu-acetylethTSC. Each treatment group and the controls were read in triplicates and the data were plotted as percentage cell viability versus concentration of the complex. Dose-response curves were generated based on the cell viability data obtained, and IC50 values were calculated. Cardiomyocytes (H9C2) were also cultured and used to test cytotoxicity in non-malignant cells. Results: Cell viability was inhibited in a dose-dependent manner in all the selected cancer cell lines whiles that of H9C2 was not significantly affected. Conclusion: This indicates that Cu-acetylethTSC was selective for malignant cells. Further studies are underway to understand the efficacy, protein targets, and underlying mechanisms of the role of Cu- acetylethTSC. | en_US |
dc.description.sponsorship | Grant from the Cancer Prevention and Research Institute of Texas. | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12503/32123 | |
dc.language.iso | en | |
dc.title | Anti-proliferative effects of a copper(II) complex with a thiosemicarbazone ligand against selected human cancer cells | en_US |
dc.type | poster | en_US |
dc.type.material | text | en_US |